pearl therapeutics
AstraZeneca to pay up to $1.2 billion for Pearl
June 10, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, pearl therapeutics
AstraZeneca is betting big on lung disease specialist Pearl Therapeutics as it looks to spend $1.2 billion to acquire the …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
